An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins - PubMed (original) (raw)
. 1996 Feb 1;183(2):527-34.
doi: 10.1084/jem.183.2.527.
R C Hendrickson, P H Gulden, V Brichard, A Van Pel, Y Chen, J Shabanowitz, T Wolfel, C L Slingluff Jr, T Boon, D F Hunt, V H Engelhard
Affiliations
- PMID: 8627164
- PMCID: PMC2192446
- DOI: 10.1084/jem.183.2.527
An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins
J C Skipper et al. J Exp Med. 1996.
Abstract
T lymphocytes recognize antigens consisting of peptides presented by class I and II major histocompatibility complex (MHC) molecules. The peptides identified so far have been predictable from the amino acid sequences of proteins. We have identified the natural peptide target of a CTL clone that recognizes the tyrosinase gene product on melanoma cells. The peptide results from posttranslational conversion of asparagine to aspartic acid. This change is of central importance for peptide recognition by melanoma-specific T cells, but has no impact on peptide binding to the MHC molecule. This posttranslational modification has not been previously described for any MHC-associated peptide and represents the first demonstration of posttranslational modification of a naturally processed class I-associated peptide. This observation is relevant to the identification and prediction of potential peptide antigens. The most likely mechanism for production of this peptide leads to the suggestion that antigenic peptides can be derived from proteins that are translated into the endoplasmic reticulum.
Similar articles
- Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
Kawakami Y, Robbins PF, Wang X, Tupesis JP, Parkhurst MR, Kang X, Sakaguchi K, Appella E, Rosenberg SA. Kawakami Y, et al. J Immunol. 1998 Dec 15;161(12):6985-92. J Immunol. 1998. PMID: 9862734 - Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase.
Riley JP, Rosenberg SA, Parkhurst MR. Riley JP, et al. J Immunother. 2001 May-Jun;24(3):212-20. J Immunother. 2001. PMID: 11394498 - Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376.
Valmori D, Pittet MJ, Vonarbourg C, Rimoldi D, Liénard D, Speiser D, Dunbar R, Cerundolo V, Cerottini JC, Romero P. Valmori D, et al. Cancer Res. 1999 Aug 15;59(16):4050-5. Cancer Res. 1999. PMID: 10463606 - Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes.
Kang X, Kawakami Y, el-Gamil M, Wang R, Sakaguchi K, Yannelli JR, Appella E, Rosenberg SA, Robbins PF. Kang X, et al. J Immunol. 1995 Aug 1;155(3):1343-8. J Immunol. 1995. PMID: 7543520 - Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes.
Wölfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Büschenfelde KH, Boon T. Wölfel T, et al. Eur J Immunol. 1994 Mar;24(3):759-64. doi: 10.1002/eji.1830240340. Eur J Immunol. 1994. PMID: 8125142
Cited by
- Innovations Toward Immunopeptidomics.
Abelin JG, Cox AL. Abelin JG, et al. Mol Cell Proteomics. 2024 Sep;23(9):100823. doi: 10.1016/j.mcpro.2024.100823. Epub 2024 Jul 31. Mol Cell Proteomics. 2024. PMID: 39095021 Free PMC article. Review. - Tumor Antigens beyond the Human Exome.
Emilius L, Bremm F, Binder AK, Schaft N, Dörrie J. Emilius L, et al. Int J Mol Sci. 2024 Apr 25;25(9):4673. doi: 10.3390/ijms25094673. Int J Mol Sci. 2024. PMID: 38731892 Free PMC article. Review. - Non-mutational neoantigens in disease.
Stern LJ, Clement C, Galluzzi L, Santambrogio L. Stern LJ, et al. Nat Immunol. 2024 Jan;25(1):29-40. doi: 10.1038/s41590-023-01664-1. Epub 2024 Jan 2. Nat Immunol. 2024. PMID: 38168954 Free PMC article. Review. - Methionine oxidation selectively enhances T cell reactivity against a melanoma antigen.
Chiriţoiu GN, Munteanu CVA, Şulea TA, Spiridon L, Petrescu AJ, Jandus C, Romero P, Petrescu ŞM. Chiriţoiu GN, et al. iScience. 2023 Jun 25;26(7):107205. doi: 10.1016/j.isci.2023.107205. eCollection 2023 Jul 21. iScience. 2023. PMID: 37485346 Free PMC article. - Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer.
Hu C, Liu M, Li Y, Zhao Y, Sharma A, Liu H, Schmidt-Wolf IGH. Hu C, et al. Front Immunol. 2023 Jun 29;14:1213716. doi: 10.3389/fimmu.2023.1213716. eCollection 2023. Front Immunol. 2023. PMID: 37457699 Free PMC article. Review.
References
- Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10275-9 - PubMed
- J Immunol. 1993 Aug 1;151(3):1654-62 - PubMed
- J Exp Med. 1994 Mar 1;179(3):1005-9 - PubMed
- J Exp Med. 1994 Mar 1;179(3):921-30 - PubMed
- Eur J Immunol. 1994 Mar;24(3):759-64 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials